5 results on '"Carone, Mauro"'
Number of results to display per page
Search Results
2. Mortality in obstructive sleep apnea syndrome (OSAS) and overlap syndrome (OS): The role of nocturnal hypoxemia and CPAP compliance
- Author
-
Tondo, Pasquale, Scioscia, Giulia, Sabato, Roberto, Leccisotti, Rosa, Hoxhallari, Anela, Sorangelo, Simone, Mansueto, Giuseppe, Campanino, Terence, Carone, Mauro, Foschino Barbaro, Maria Pia, and Lacedonia, Donato
- Published
- 2023
- Full Text
- View/download PDF
3. Age and comorbidities are crucial predictors of mortality in severe obstructive sleep apnoea syndrome
- Author
-
Scrutinio, Domenico, Guida, Pietro, Aliani, Maria, Castellana, Giorgio, Guido, Patrizia, and Carone, Mauro
- Published
- 2021
- Full Text
- View/download PDF
4. An international perspective on hospitalized patients with viral community-acquired pneumonia
- Author
-
Aruj, Patricia Karina, Attorri, Silvia, Barimboim, Enrique, Caeiro, Juan Pablo, Garzón, María I., Cambursano, Victor Hugo, Ceccato, Adrian, Chertcoff, Julio, Cordon Díaz, Ariel, de Vedia, Lautaro, Ganaha, Maria Cristina, Lambert, Sandra, Lopardo, Gustavo, Luna, Carlos M., Malberti, Alessio Gerardo, Morcillo, Nora, Tartara, Silvina, Pensotti, Claudia, Pereyra, Betiana, Scapellato, Pablo Gustavo, Stagnaro, Juan Pablo, Shah, Sonali, Lötsch, Felix, Thalhammer, Florian, Anseeuw, Kurt, Francois, Camille A., Van Braeckel, Eva, Vincent, Jean Louis, Djimon, Marcel Zannou, Aranha Nouér, Simone, Chipev, Peter, Encheva, Milena, Miteva, Darina, Petkova, Diana, Balkissou, Adamou Dodo, Pefura Yone, Eric Walter, Mbatchou Ngahane, Bertrand Hugo, Shen, Ning, Xu, Jin-fu, Bustamante Rico, Carlos Andres, Buitrago, Ricardo, Pereira Paternina, Fernando Jose, Kayembe Ntumba, Jean-Marie, Vladic-Carevic, Vesna, Jakopovic, Marko, Matkovic, Zinka, Mitrecic, Ivan, Bouchy Jacobsson, Marie-Laure, Bro Christensen, Anette, Bødtger, Uffe, Meyer, Christian Niels, Vestergaard Jensen, Andreas, El-Said Abd El-Wahhab, Ibrahim, Elsayed Morsy, Nesreen, Shafiek, Hanaa, Sobh, Eman, Abdulsemed, Kedir Abdella, Bertrand, Fabrice, Brun-Buisson, Christian, de Montmollin, Etienne, Fartoukh, Muriel, Messika, Jonathan, Tattevin, Pierre, Khoury, Abdo, Ebruke, Bernard, Dreher, Michael, Kolditz, Martin, Meisinger, Matthias, Pletz, Mathias W., Hagel, Stefan, Rupp, Jan, Schaberg, Tom, Spielmanns, Marc, Creutz, Petra, Suttorp, Norton, Siaw-Lartey, Beatrice, Dimakou, Katerina, Papapetrou, Dimosthenis, Tsigou, Evdoxia, Ampazis, Dimitrios, Kaimakamis, Evangelos, Bhatia, Mohit, Dhar, Raja, D’Souza, George, Garg, Rajiv, Koul, Parvaiz A., Jayaraj, B.S., Narayan, Kiran Vishnu, Udnur, Hirennappa B., Krishnamurthy, Shashi Bhaskara, Kant, Surya, Swarnakar, Rajesh, Salvi, Sundeep, Limaye, Sneha, Golshani, Keihan, Keatings, Vera M., Martin-Loeches, Ignacio, Maor, Yasmin, Strahilevitz, Jacob, Battaglia, Salvatore, Carrabba, Maria, Ceriana, Piero, Confalonieri, Marco, d’Arminio Monforte, Antonella, Del Prato, Bruno, De Rosa, Marino, Fantini, Riccardo, Fiorentino, Giuseppe, Gammino, Maria Antonia, Menzella, Francesco, Milani, Giuseppe, Nava, Stefano, Palmiero, Gerardo, Petrino, Roberta, Gabrielli, Barbra, Rossi, Paolo, Sorino, Claudio, Steinhilber, Gundi, Zanforlin, Alessandro, Franzetti, Fabio, Carone, Mauro, Patella, Vincenzo, Scarlata, Simone, Comel, Andrea, Kurahashi, Kiyoyasu, Aoun Bacha, Zeina, Barajas Ugalde, Daniel, Ceballos Zuñiga, Omar, Villegas, José F., Medenica, Milic, van de Garde, E.M.W., Raj Mihsra, Deebya, Shrestha, Poojan, Ridgeon, Elliott, Ishola Awokola, Babatunde, Nwankwo, Ogonna N.O., Olufunlola, Adefuye Bolanle, Olumide, Segaolu, Ukwaja, Kingsley N., Irfan, Muhammad, Minarowski, Lukasz, Szymon, Skoczyński, Froes, Felipe, Leuschner, Pedro, Meireles, Mariana, Ferrão, Cláudia, Neves, João, Ravara, Sofia B., Brocovschii, Victoria, Ion, Chesov, Rusu, Doina, Toma, Cristina, Chirita, Daniela, Dorobat, Carmen Mihaela, Birkun, Alexei, Kaluzhenina, Anna, Almotairi, Abdullah, Bukhary, Zakeya Abdulbaqi Ali, Edathodu, Jameela, Fathy, Amal, Mushira Abdulaziz Enani, Abdullah, Eltayeb Mohamed, Nazik, Ulhadi Memon, Jawed, Bella, Abdelhaleem, Bogdanović, Nada, Milenkovic, Branislava, Pesut, Dragica, Borderìas, Luis, Bordon Garcia, Noel Manuel, Cabello Alarcón, Hugo, Cilloniz, Catia, Torres, Antoni, Diaz-Brito, Vicens, Casas, Xavier, Encabo González, Alicia, Fernández-Almira, Maria Luisa, Gallego, Miguel, Gaspar-GarcÍa, Inmaculada, González Del Castillo, Juan, Javaloyes Victoria, Patricia, Laserna Martínez, Elena, Malo de Molina, Rosa, Menéndez, Rosario, Pando-Sandoval, Ana, Prat Aymerich, Cristina, Lacoma de la Torre, Alicia, García-Olivé, Ignasi, Rello, Jordi, Moyano, Silvia, Sanz, Francisco, Sibila, Oriol, Rodrigo-Troyano, Ana, Solé-Violán, Jordi, Uranga, Ane, van Boven, Job F.M., Vendrell Torra, Ester, Pujol, Jordi Almirall, Feldman, Charles, Kee Yum, Ho, Fiogbe, Arnauld Attannon, Yangui, Ferdaous, Bilaceroglu, Semra, Dalar, Levent, Yilmaz, Ufuk, Bogomolov, Artemii, Elahi, Naheed, Dhasmana, Devesh J., Feneley, Andrew, Hancock, Carole, Hill, Adam T., Rudran, Banu, Ruiz-Buitrago, Silvia, Campbell, Marion, Whitaker, Paul, Youzguin, Alexander, Singanayagam, Anika, Allen, Karen S., Brito, Veronica, Dietz, Jessica, Dysart, Claire E., Kellie, Susan M., Franco-Sadud, Ricardo A., Meier, Garnet, Gaga, Mina, Holland, Thomas L., Bergin, Stephen P., Kheir, Fayez, Landmeier, Mark, Lois, Manuel, Nair, Girish B., Patel, Hemali, Reyes, Katherine, Rodriguez-Cintron, William, Saito, Shigeki, Soni, Nilam J., Noda, Julio, Hinojosa, Cecilia I., Levine, Stephanie M., Angel, Luis F., Anzueto, Antonio, Scott Whitlow, K., Hipskind, John, Sukhija, Kunal, Totten, Vicken, Wunderink, Richard G., Shah, Ray D., Mateyo, Kondwelani John, Carugati, Manuela, Morosi, Manuela, Monge, Elisa, Radovanovic, Dejan, Sotgiu, Giovanni, Jankovic, Mateja, Mahesh, Padukudru Anand, Marcos, Pedro Jorge, Abdalla, Mohamed I., Di Pasquale, Marta Francesca, Gramegna, Andrea, Terraneo, Silvia, Blasi, Francesco, Santus, Pierachille, Aliberti, Stefano, Reyes, Luis F., and Restrepo, Marcos I.
- Published
- 2019
- Full Text
- View/download PDF
5. Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation: The ICSLIFE pragmatic, randomised controlled study.
- Author
-
Papi, Alberto, Forini, Giacomo, Maniscalco, Mauro, Bargagli, Elena, Crimi, Claudia, Santus, Pierachille, Molino, Antonio, Bandiera, Valeria, Baraldi, Federico, D'Anna, Silvestro Ennio, Carone, Mauro, Marvisi, Maurizio, Pelaia, Corrado, Scioscia, Giulia, Patella, Vincenzo, Aliani, Maria, and Fabbri, Leonardo M
- Subjects
- *
CHRONIC obstructive pulmonary disease , *CHRONIC bronchitis , *HEART failure , *COMORBIDITY , *CARDIOVASCULAR diseases - Abstract
• Patients with comorbid cardiovascular and chronic obstructive pulmonary disease (COPD) and a recent hospitalised exacerbation, although common, are typically excluded from studies. • However, these patients are at increased risk of rehospitalisation and death. • This pragmatic study examined the effect of the addition of inhaled corticosteroid (ICS) to long-acting bronchodilators in these patients; unfortunately the planned number of patients was not recruited, limiting the strength of the conclusions. • The results suggest that ICS use does not reduce rehospitalisation/death (primary outcome), although all-cause and cardiovascular mortality rates were reduced. • Results also suggest that ICS use did not increase the risk of adverse events and/or pneumonia. Patients with chronic obstructive pulmonary disease (COPD) frequently have cardiovascular comorbidities, increasing the risk of hospitalised COPD exacerbations (H-ECOPDs) or death. This pragmatic study examined the effects of adding an inhaled corticosteroid (ICS) to long-acting bronchodilator(s) (LABDs) in patients with COPD and cardiac comorbidities who had a recent H-ECOPD. Patients >60 years of age with COPD and ≥1 cardiac comorbidity, within 6 months after discharge following an H-ECOPD, were randomised to receive LABD(s) with or without ICS, and were followed for 1 year. The primary outcome was the time to first rehospitalisation and/or all-cause death. The planned number of patients was not recruited (803/1032), limiting the strength of the conclusions. In the intention-to-treat population, 89/403 patients (22.1 %) were rehospitalised or died in the LABD group (probability 0.257 [95 % confidence interval 0.206, 0.318]), vs 85/400 (21.3 %) in the LABD+ICS group (0.249 [0.198, 0.310]), with no difference between groups in time-to-event (hazard ratio 1.116 [0.827, 1.504]; p = 0.473). All-cause and cardiovascular mortality were lower in patients receiving LABD(s)+ICS, with relative reductions of 19.7 % and 27.4 %, respectively (9.8 % vs 12.2 % and 4.5 % vs 6.2 %), although the groups were not formally statistically compared for these endpoints. Fewer patients had adverse events in the LABD+ICS group (43.0 % vs 50.4 %; p = 0.013), with 4.9 % vs 5.4 % reporting pneumonia adverse events. Results suggest addition of ICS to LABDs did not reduce the time-to-combined rehospitalisation/death, although it decreased all-cause and cardiovascular mortality. ICS use was not associated with an increased risk of adverse events, particularly pneumonia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.